golnerminogene pradenovec

AXP000150.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, E1-deleted, radiation-inducible EGR1 promoter)
Targets
TNF
Originator
GenVec
Sponsor
GenVec

Names

NameTypeSource
golnerminogene pradenovecpreferred name, INNcurator, ncit
TNFeradebrandncit
ADgv EGR.TNF.11Dcodencit
Ad 5-TNF Alpha ambiguoussynonymncit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
E1-deleted adenoviral vector; human TNF-alpha under the radiation-inducible EGR1 promoter
Transgenes
TNF
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C26444

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT01048151TNFerade Biologic to Treat Locally Advanced Prostate CancerUnknownPhase 120Locally Advanced Prostate Cancer
NCT00496535A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck CancerCompletedPhase 1/2Head and Neck Cancer; Head and Neck Neoplasms
NCT00496236Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck CancerCompletedPhase 1/2Head and Neck Cancer; Head and Neck Neoplasms
NCT00261404TNFerade™ Biologic Plus Radiation for Metastatic MelanomaCompletedPhase 2Melanoma
NCT00137878TNFerade™ Plus Chemo/Radiation/Surgery for Rectal CancerCompletedPhase 2Rectal Cancer
NCT00051480Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal CancerCompletedPhase 2Esophageal Cancer
NCT00051467A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic CancerCompletedPhase 3Pancreatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 23104721A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.Annals of oncology : official journal of the European Society for Medical Oncology2013name in title: ADgv EGR.TNF.11D
PMID 23341531Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2013cited by trial NCT00051467
PMID 22248601EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.Gastrointestinal endoscopy2012name in title: TNFerade
PMID 22520270Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.Gastrointestinal endoscopy2012cited by trial NCT00051480
PMID 21447969A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.Oncology2010name in title: TNFerade
PMID 19734632Surgical resection after TNFerade therapy for locally advanced pancreatic cancer.JOP : Journal of the pancreas2009name in title: TNFerade
PMID 18253139Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer.Nature clinical practice. Gastroenterology & hepatology2008name in abstract: TNFerade
PMID 17653822Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.Clinical & experimental metastasis2007name in abstract: TNFerade
PMID 16132372TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.Annals of surgical oncology2005name in title: TNFerade
PMID 14726502TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2004name in title: TNFerade
PMID 15355902A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.Clinical cancer research : an official journal of the American Association for Cancer Research2004name in title: TNFerade

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 26600634TNFerade, an innovative cancer immunotherapeutic.Indian journal of pharmacology2015name in title: TNFerade
PMID 23852521Radiation oxygen biology with pulse electron paramagnetic resonance imaging in animal tumors.Advances in experimental medicine and biology2013name in abstract: TNFerade
PMID 21222122The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark.World journal of surgery2011name in abstract: TNFerade
PMID 21880146Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.Molecular cancer2011name in abstract: TNFerade
PMID 21103287The society for gastrointestinal intervention. Are we, as an organization of disparate disciplines, cooperative or competitive?Gut and liver2010name in abstract: TNFerade
PMID 18974777Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.Cancer gene therapy2009name in abstract: TNFerade
PMID 19444302Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.Cancer gene therapy2009name in title: TNFerade
PMID 19444305Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.Cancer gene therapy2009name in abstract: TNFerade
PMID 16082378Ionizing radiation: a genetic switch for cancer therapy.Cancer gene therapy2006name in abstract: TNFerade
PMID 14726507TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2004name in title: TNFerade
PMID 14508100Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology.Cancer biology & therapy2003name in abstract: TNFerade
PMID 14513689Technology evaluation: TNFerade, GenVec.Current opinion in molecular therapeutics2003name in title: TNFerade
PMID 12386834TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.Cancer gene therapy2002name in title: TNFerade
PMID 11399232Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.Human gene therapy2001name in title: TNFerade

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA113662DNA Damage Targeted Gene Therapy in Head & Neck CancerUNIVERSITY OF CHICAGOWEICHSELBAUM, RALPH R2005–2009name in abstract: TNFerade
R21CA115018KLH-pulsed dendritic cells plus TNFerade in Pancreatic CancerEAST CAROLINA UNIVERSITYZERVOS, EMMANUEL E2006–2007name in title: TNFerade
R43CA105733Activation of the Immune System by TNFeradeGENVEC, INC.KING, C. RICHTER2004–2004name in title: TNFerade

Notes

TNFerade: adenovirus carrying human TNF-alpha under the radiation-inducible EGR1 promoter, injected into the tumour and combined with radiotherapy. Reached a phase 3 trial in locally advanced pancreatic cancer (NCT00051467) with 5-fluorouracil and radiation, which did not improve survival. Construct name ADGVEGR.TNF.11D.

How to cite

golnerminogene pradenovec (AXP000150.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000150.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.